[PDF] Efficacy and Tolerability of Eight Antimicrobial Regimens in the Outpatient Treatment of Exacerbations of Chronic Obstructive Pulmonary Disease | Semantic Scholar (2024)

The findings suggest high efficacy and good tolerability of moxifloxacin in the treatment of moderate COPD exacerbations of bacterial origin.

The findings supported the use of levofloxacin 750 mg as an alternative antibiotic in the treatment of COPD exacerbations due to its high efficacy and good tolerability.

The efficacy of Mox ifloxacin was better than Ceftriaxone in acute exacerbation of chronic obstructive pulmonary disease and the efficacy of the oral Moxifl Coxacin group was significantly better than the oral CeftRIaxone group (p-value, < 0.05).

The findings suggest high efficacy and safety of all studied regimens in the treatment of exacerbations of chronic bronchitis and COPD.

Even though the clinical cure rates in this study were similar at 10 days, the time to resolution of symptoms was shorter in the patients in the moxifloxacin group than in the other two groups, and the aim of antimicrobial therapy should be to reduce both the rate of therapeutic failure and the duration of symptoms.

The use of third-line antimicrobials, co-amoxiclav, ciprofloxacin or azithromycin, significantly reduced the failure rate and need for hospitalization, prolonged the time between A ECB episodes, and showed a lower total cost for the management of AECB.

There was a significant benefit associated with antibiotic and Peak flow recovered more rapidly with antibiotic treatment than with placebo, and side effects were uncommon and did not differ between antibiotic and placebo.

The bacterial etiology of AECOPD is reviewed and clinical trials that support the use of antibiotics for AECopD are reviewed, with an emphasis on the role of newer fluoroquinolones for the treatment of patients with this condition.

The MAESTRAL study showed that moxifloxacin was as effective as amoxicillin/clavulanic acid in the treatment of outpatients with AECOPD and both therapies were well tolerated.

Moxifloxacin significantly reduced time to recovery from AE-COPD in patients with moderate to severe disease by approximately 20% compared with other antimicrobials, which should result in earlier return to work or normal activities, and to social and economic savings.

The presence of green, purulent sputum was 94.4% sensitive and 77.0% specific for the yield of a high bacterial load and indicates a clear subset of patient episodes identified at presentation that is likely to benefit most from antibiotic therapy.

The management of chronic stable COPD always includes smoking cessation and oxygen therapy, and patients who do not respond to standard therapies may benefit from surgery.

The association between an exacerbation and the isolation of a new strain of a bacterial pathogen supports the causative role of bacteria in exacerbations of chronic obstructive pulmonary disease.

...

...